首頁 > 市場調查報告書 > 製藥

孤兒藥

市場調查報告書

商品編碼

1485257

嗜中性白血球減少症治療市場規模 - 依治療類型、藥物類型、給藥途徑、適應症、配銷通路、全球預測，2024 年 - 2032 年

Neutropenia Treatment Market Size - By Treatment Type, Drug Type, Route of Administration, Indication, Distribution Channel, Global Forecast, 2024 - 2032

出版日期: 2024年03月08日 | 出版商:

Global Market Insights Inc. | 英文 170 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

由於癌症、自體免疫疾病和傳染病等通常與中性粒細胞減少症相關的疾病盛行率不斷上升，預計中性粒細胞減少症治療市場在2024 年至2032 年間將以超過4.1% 的複合年成長率成長。根據世界衛生組織的數據，2022 年，約有 2,000 萬新診斷癌症病例和 970 萬人死亡。隨著這些潛在疾病的發生率在全球範圍內不斷上升，需要中性粒細胞減少症治療的患者人數也相應增加。此外，醫療技術和藥物開發的進步導致了新療法和治療方式的引入，以提高療效和安全性。

由於與年齡相關的免疫系統變化以及慢性病患病率較高，老年人更容易患中性粒細胞減少症，因此對中性粒細胞減少症治療的需求更大。此外，人們越來越認知到早期發現和管理中性粒細胞減少症的重要性，再加上獲得醫療服務和診斷的機會的改善，將提高患者的診斷率和尋求治療的行為。

中性粒細胞減少症治療市場分為治療類型、藥物類型、給藥途徑、適應症、配銷通路和區域。

有跡象表明，特發性中性粒細胞減少症領域的行業規模將在2024 年至2032 年期間以4% 的複合年成長率獲得顯著成長，其特點是中性粒細胞計數在沒有明確原因的情況下減少。由於根本原因尚不清楚，人們越來越重視症狀管理和支持性護理，以減輕感染風險並提高患者的生活品質。此外，醫學研究的進步和對免疫系統的了解導致了標靶治療和免疫調節劑的開發，這些藥物在有效治療特發性中性粒細胞減少症方面顯示出希望。

根據藥物類型，生物相似藥領域的中性粒細胞減少症治療市場預計在 2024 年和 2032 年複合年成長率為 4.8%，因為它們為原研生物藥提供了具有成本效益的替代品。隨著全球醫療保健系統尋求在不影響患者護理的情況下控制成本，生物相似藥的可負擔性和可用性正在推動其在中性粒細胞減少症治療方案中的採用。此外，生物相似藥經過嚴格的監管審查，以證明其與參考生物製劑具有可比性的功效和安全性，從而增強了醫療保健提供者和患者的信心。

由於人口迅速成長和傳染病患者病率的增加，預計 2024 年至 2032 年亞太地區中性粒細胞減少症治療行業規模將以 4.8% 的複合年成長率成長。中國和印度等國家醫療基礎設施的改善和醫療支出的增加增加了中性粒細胞減少症診斷和治療的機會。醫療保健專業人員和患者對中性粒細胞減少症的認知不斷提高，加上醫學研究和治療方案的進步，將進一步刺激亞太地區的市場擴張。

產業生態系統分析
產業影響力
- 成長動力
  - 中性粒細胞減少症盛行率增加
  - 化療的使用不斷增加
  - 旨在提高意識的政府措施和支持
  - 不斷加強的研發力道擴大了強大的藥物管道
  - 藥物傳輸技術不斷進步
  - 優惠的報銷政策支持治療的可及性
- 產業陷阱與挑戰
  - 嚴格的產品審核規定
  - 與治療相關的不良反應
成長潛力分析
管道評估
報銷場景
監管環境
波特的分析
PESTEL分析

第 4 章：競爭格局

介紹
公司矩陣分析
主要市場參與者的競爭分析
競爭定位矩陣
戰略儀表板

第 5 章：市場估計與預測：按治療類型，2018-2032 年

主要趨勢
集落刺激因子 (CSF)
抗生素
抗黴菌藥
抗病毒藥
其他治療類型

第 6 章：市場估計與預測：按藥物類型，2018-2032

主要趨勢
品牌化
生物相似藥

第 7 章：市場估計與預測：按管理途徑，2018-2032 年

主要趨勢
口服
注射用

第 8 章：市場估計與預測：按指標分類，2018-2032 年

主要趨勢
化療引起的中性白血球減少症
週期性嗜中性白血球減少症
特發性嗜中性白血球減少症
先天性中性白血球減少症

第 9 章：市場估計與預測：按配銷通路，2018-2032

主要趨勢
醫院藥房
零售藥局
網路藥局

第 10 章：市場估計與預測：按地區分類，2018 年 - 2032 年

主要動向：按地區
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 英國
- 法國
- 西班牙
- 義大利
- 歐洲其他地區
亞太地區
- 日本
- 中國
- 印度
- 澳洲
- 亞太地區其他地區
拉丁美洲
- 巴西
- 墨西哥
- 拉丁美洲其他地區
中東和非洲
- 南非
- 沙烏地阿拉伯
- 中東和非洲其他地區

第 11 章：公司簡介

Amgen Inc.
BeyondSpring Inc.
Biocon Biologics Inc.
Cellerant Therapeutics
Coherus BioSciences, Inc.
CuraTeQ Biologics Pvt. Ltd.
Evive Biotech
Kyowa Kirin Co., Ltd.
Pfizer Inc.
Sandoz Inc.
Spectrum Pharmaceuticals
Teva Pharmaceutical Industries Ltd.

簡介目錄

Product Code: 8441

Neutropenia treatment market is anticipated to grow at over 4.1% CAGR between 2024 and 2032, driven by the increasing prevalence of conditions, such as cancer, autoimmune disorders, and infectious diseases, which are often associated with neutropenia. As per WHO, in 2022, there were approximately 20 million newly diagnosed cancer cases and 9.7 million fatalities. As the incidence of these underlying conditions is rising globally, there is a corresponding increase in the number of patients requiring neutropenia treatment. Additionally, advancements in medical technology and drug development have led to the introduction of novel therapies and treatment modalities for offering improved efficacy and safety profiles.

As older adults are more susceptible to neutropenia due to age-related changes in the immune system and the higher prevalence of chronic diseases, there is a greater demand for neutropenia treatment. Moreover, the increasing awareness about the importance of early detection and management of neutropenia coupled with improved access to healthcare services and diagnostics will drive the diagnosis rate and treatment-seeking behavior among patients.

The neutropenia treatment market is segmented into treatment type, drug type, route of administration, indication, distribution channel, and region.

By indication, the industry size from the idiopathic neutropenia segment will gain significant traction at 4% CAGR during 2024-2032, characterized by the decrease in neutrophil counts without an identifiable cause. As the underlying cause remains unclear, there is a growing emphasis on symptom management and supportive care to alleviate the risk of infections and improve the quality of life of patients. Additionally, advancements in medical research and understanding of the immune system have led to the development of targeted therapies and immunomodulatory agents that show promise in managing idiopathic neutropenia effectively.

Based on drug type, the neutropenia treatment market from the biosimilar drugs segment is anticipated to witness 4.8% CAGR throughout 2024 and 2032, as they offer cost-effective alternatives to originator biologic drugs. With healthcare systems worldwide seeking to contain costs without compromising patient care, the affordability and availability of biosimilar drugs is driving their adoption in neutropenia treatment regimens. Additionally, biosimilar drugs undergo rigorous regulatory scrutiny to demonstrate comparable efficacy and safety profiles to their reference biologics, instilling confidence among healthcare providers and patients.

Asia Pacific neutropenia treatment industry size is anticipated to grow at 4.8% CAGR over 2024-2032, attributed to the rapidly expanding population and increasing prevalence of infectious diseases. Improving healthcare infrastructure and rising healthcare expenditure in countries like China and India have enhanced the access to neutropenia diagnosis and treatment. The growing awareness about neutropenia among healthcare professionals and patients coupled with advancements in medical research and treatment options will further stimulate the market expansion in the Asia Pacific region.

Chapter 1 Methodology & Scope

1.1 Market scope & definitions
1.2 Base estimates & calculations
1.3 Forecast parameters
1.4 Data collection
1.5 Data validation
1.6 Data sources
- 1.6.1 Primary
- 1.6.2 Secondary
  - 1.6.2.1 Paid sources
  - 1.6.2.2 Public sources

Chapter 2 Executive Summary

2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Increasing prevalence of neutropenia
  - 3.2.1.2 Growing utilization of chemotherapy
  - 3.2.1.3 Government initiatives and support aimed at raising awareness
  - 3.2.1.4 Rising R&D efforts expand robust drug pipeline
  - 3.2.1.5 Increasing advancements in pharmaceutical drug delivery technology
  - 3.2.1.6 Favorable reimbursement policies support treatment accessibility
- 3.2.2 Industry pitfalls & challenges
  - 3.2.2.1 Stringent regulations for product approvals
  - 3.2.2.2 Adverse effects associated with the treatment
3.3 Growth potential analysis
3.4 Pipeline assessment
3.5 Reimbursement scenario
3.6 Regulatory landscape
3.7 Porter's analysis
- 3.7.1 Supplier power
- 3.7.2 Buyer power
- 3.7.3 Threat of new entrants
- 3.7.4 Threat of substitutes
- 3.7.5 Industry rivalry
3.8 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company matrix analysis
4.3 Competitive analysis of major market players
4.4 Competitive positioning matrix
4.5 Strategic dashboard

Chapter 5 Market Estimates and Forecast, By Treatment Type, 2018-2032 ($ Million)

5.1 Key trends
5.2 Colony-stimulating factors (CSFs)
5.3 Antibiotics
5.4 Antifungals
5.5 Antivirals
5.6 Other treatment types

Chapter 6 Market Estimates and Forecast, By Drug Type, 2018-2032 ($ Million)

6.1 Key trends
6.2 Branded
6.3 Biosimilars

Chapter 7 Market Estimates and Forecast, By Route of Administration, 2018-2032 ($ Million)

7.1 Key trends
7.2 Oral
7.3 Parenteral

Chapter 8 Market Estimates and Forecast, By Indication, 2018-2032 ($ Million)

8.1 Key trends
8.2 Chemotherapy-induced neutropenia
8.3 Cyclic neutropenia
8.4 Idiopathic neutropenia
8.5 Congenital neutropenia

Chapter 9 Market Estimates and Forecast, By Distribution Channel, 2018-2032 ($ Million)

9.1 Key trends
9.2 Hospital pharmacies
9.3 Retail pharmacies
9.4 Online pharmacies

Chapter 10 Market Estimates and Forecast, By Region, 2018 - 2032 ($ Million)

10.1 Key trends, by region
10.2 North America
- 10.2.1 U.S.
- 10.2.2 Canada
10.3 Europe
- 10.3.1 Germany
- 10.3.2 UK
- 10.3.3 France
- 10.3.4 Spain
- 10.3.5 Italy
- 10.3.6 Rest of Europe
10.4 Asia Pacific
- 10.4.1 Japan
- 10.4.2 China
- 10.4.3 India
- 10.4.4 Australia
- 10.4.5 Rest of Asia Pacific
10.5 Latin America
- 10.5.1 Brazil
- 10.5.2 Mexico
- 10.5.3 Rest of Latin America
10.6 Middle East and Africa
- 10.6.1 South Africa
- 10.6.2 Saudi Arabia
- 10.6.3 Rest of Middle East and Africa